Cedazuridine

DRUG6 trials

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia (CMML)Healthy VolunteersMyelodysplastic Syndrome/NeoplasmMyelodysplastic SyndromesMyelodysplastic Syndromes (MDS)Recurrent Acute Myeloid Leukemia

Phase 1

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Active, not recruitingNCT03875287

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSolid Tumor

Start: 2019-04-17End: 2027-09-01Target: 35Updated: 2026-09-08

Thorough QT Assessment of Cedazuridine in Healthy Subjects

CompletedNCT04953923

Astex Pharmaceuticals, Inc.Healthy Volunteers

Start: 2021-07-01End: 2021-11-16Updated: 2024-08-02

Phase 2

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RecruitingNCT04256317

Taiho Oncology, Inc.Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome/Neoplasm +1

Start: 2020-05-21End: 2028-11-01Target: 316Updated: 2026-04-30

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

WithdrawnNCT04985656

TakedaMyelodysplastic Syndromes (MDS)

Start: 2021-10-01End: 2024-11-08Updated: 2021-09-29

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

TerminatedNCT05799079

Sanjay MohanRecurrent Acute Myeloid Leukemia

Start: 2023-04-13End: 2024-09-20Updated: 2026-01-09

Phase 3

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

RecruitingCTIS2024-515098-93-00

Taiho Oncology Inc.Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndromes (MDS)

Start: 2025-07-22Target: 588Updated: 2025-12-29

Related Papers

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Blood2025-11-03

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)